X0508 4 2025-05-28 0001885522 Neumora Therapeutics, Inc. NMRA 0001602343 Piacquad David C/O NEUMORA THERAPEUTICS, INC. 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 true false false false false Stock Option (Right to Buy) 1.69 2025-05-28 4 D false 46455 D 2033-09-14 Common Stock 46455 0 D Stock Option (Right to Buy) 1.69 2025-05-28 4 D false 28571 D 2034-06-13 Common Stock 28571 0 D Stock Option (Right to Buy) 0.72 2025-05-28 4 A false 46455 A 2033-09-14 Common Stock 46455 46455 D Stock Option (Right to Buy) 0.72 2025-05-28 4 A false 28571 A 2034-06-13 Common Stock 28571 28571 D Stock Option (Right to Buy) 0.72 2025-05-28 4 A false 80000 0 A 2035-05-27 Common Stock 80000 80000 D 1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024. On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025. /s/ Michael Milligan, as Attorney-in-Fact for David Piacquad 2025-05-30